2013 年 T3 檢驗準確性 ( Accuracy ) 測試結果報告 |
送檢批號:AQ2013-06 調查期間:2013 年 06 月 03 ~
10 日 參加單位數:21
檢驗單位 代碼 |
確診醫院 代碼 |
檢體方 法編碼 |
檢體試 劑編碼 |
Sample S1 |
Sample S2 |
||||||
(ng/dL) |
D 1 |
Z 2 |
Da% 3 |
(ng/dL) |
D 1 |
Z 2 |
Da% 3 |
||||
RH01b |
RH01 |
2 |
5 |
236 |
-24.0 |
-1.2 |
-39% |
69 |
-5.0 |
-0.8 |
-28% |
RH07b |
RH07 |
2 |
3 |
237 |
-23.0 |
-1.1 |
-37% |
69 |
-5.0 |
-0.8 |
-28% |
RH14 |
RH14 |
2 |
3 |
246 |
-14.0 |
-0.7 |
-22% |
44 |
-30.0 |
-5.1 |
-169% |
RH15 |
RH15 |
2 |
8 |
239 |
-21.0 |
-1.0 |
-34% |
53 |
-21.0 |
-3.6 |
-118% |
CL009 |
CL009 |
2 |
5 |
233 |
-27.0 |
-1.3 |
-43% |
65 |
-9.0 |
-1.5 |
-51% |
CL010 |
CL010 |
2 |
6 |
279 |
19.0 |
0.9 |
30% |
76 |
2.0 |
0.3 |
11% |
CL012 |
CL012 |
2 |
3 |
274 |
14.0 |
0.7 |
22% |
44 |
-30.0 |
-5.1 |
-169% |
CL013 |
CL013 |
2 |
5 |
284 |
24.0 |
1.2 |
38% |
66 |
-8.0 |
-1.4 |
-45% |
CL014a |
CL014 |
2 |
3 |
281 |
21.0 |
1.0 |
34% |
59 |
-15.0 |
-2.5 |
-84% |
CL015 |
CL015 |
2 |
5 |
282 |
22.0 |
1.1 |
35% |
58 |
-16.0 |
-2.7 |
-90% |
Median of RIA Group |
260 |
62 |
|||||||||
Range of RIA Group |
233 - 284 |
44 - 76 |
|||||||||
Robust average4
of RIA Group |
259 ( n = 10 ) |
60 ( n = 10 ) |
|||||||||
Robust SD4
of RIA Group |
25.4 |
12.2 |
|||||||||
CV of RIA Group |
9.8% |
20.3% |
RH01a |
RH01 |
4 |
9 |
263 |
3.0 |
0.1 |
5% |
75 |
1.0 |
0.2 |
6% |
RH02c |
RH02 |
4 |
1 |
311 |
51.0 |
2.5 |
82% |
85 |
11.0 |
1.9 |
62% |
RH06 |
RH06 |
4 |
9 |
261 |
1.0 |
0.0 |
2% |
79 |
5.0 |
0.8 |
28% |
RH07a |
RH07 |
4 |
2 |
256 |
-4.0 |
-0.2 |
-6% |
85 |
11.0 |
1.9 |
62% |
RH12 |
RH12 |
4 |
2 |
258 |
-2.0 |
-0.1 |
-3% |
96 |
22.0 |
3.7 |
124% |
RH19 |
RH19 |
4 |
2 |
211 |
-49.0 |
-2.4 |
-79% |
81 |
7.0 |
1.2 |
39 % |
RH20 |
RH20 |
4 |
7 |
318 |
58.0 |
2.8 |
93% |
89 |
15.0 |
2.5 |
84% |
CL005 |
CL005 |
4 |
9 |
256 |
-4.0 |
-0.2 |
-6% |
81 |
7.0 |
1.2 |
39% |
CL006a |
CL006 |
4 |
1 |
273 |
13.0 |
0.6 |
21% |
76 |
2.0 |
0.3 |
11% |
CL008 |
CL008 |
4 |
1 |
287 |
27.0 |
1.3 |
43% |
80 |
6.0 |
1.0 |
34% |
CL011 |
CL011 |
4 |
13 |
275 |
15.0 |
0.7 |
24% |
99 |
25.0 |
4.2 |
141% |
Median of CLIA Group |
263 |
81 |
|||||||||
Range of CLIA Group |
211 - 318 |
75 - 99 |
|||||||||
Robust average4 of CLIA Group |
271 ( n = 11 ) |
84 ( n = 11 ) |
|||||||||
Robust SD4 of CLIA Group |
28.5 |
8.2 |
|||||||||
CV of CLIA Group |
10.5% |
9.8% |
Median of All Labs |
263 |
76 |
Range of All Labs |
211 - 318 |
44 - 99 |
Robust average4 of All Labs |
264 ( n = 21 ) |
73 ( n = 21 ) |
Robust SD4 of All Labs |
25.4 |
16.0 |
CV of All Labs |
10.2% |
12.7% |
Certified target value (Xa)*( µg/dL ) |
260 |
74 |
Uncertainty (Ua)
* |
2.6 |
0.7 |
Target SD5 |
20.8 |
5.9 |
1. D = X - Xa 2. Zscore
= D / Target SD 3. Da% (Your result from
target as percentages of allowed deviation) = D/(Xa
x MAD) x 100% 4. Robust results were
calculated by Algorithm A according to ISO 13528:2005 and IUPAC/CITAC Guide:
Selection and use of proficiency testing scheme for a limited number of
participants. Pure Appl Chem
2010;82:1099 – 135 5. Maximum allowable
deviation (MAD) 24%, Target SD = 8% |
*The
Certified Target Value of Triiodothyronine in Serum was determined using Isotope dilution
mass spectrometry (IDMS) reference method by an international certified
reference laboratory.
The reference laboratory is signatory to the
multilateral agreements of the European co-operation for Accreditation (EA)
and of the International Laboratory Accreditation Cooperation (ILAC) for the
mutual recognition of calibration certificates. The uncertainty stated is the expanded uncertainty
obtained by multiplying the standard uncertainty by the coverage factor k. At a t-distribution with v(eff) effective degrees of freedom the
value of the measured lies within the assigned range of values with a probability of 95 %. It has been determined in accordance with EA-4/02.
Reference: Thienpont
LM, Van Uytfanghe K, Beastall
G, et.al. Report of the IFCC Working Group for Standardization of Thyroid
Function Tests; Part 3:Total Thyroxine
and Total Triiodothyronine. Clin
Chem 2010; 56: 921 – 9. |
|
Sample
S1 |
Sample
S2 |
Certified Target Value (1
nmol/L = 65.1 ng/dL) |
4.001
nmol/l (260 ng/dL) |
1.139
nmol/l (74 ng/dL) |
Expanded uncertainty
|
0.04
nmol/l (2.6 ng/dL) |
0.011
nmol/l (0.7 ng/dL) |
Relative expanded uncertainty
|
1.0
% |
1.0
% |
Coverage
factor k |
2.6 |
2.6 |
Effective degrees of freedom v(eff) |
5 |
5 |
Method Name |
Method Code |
Laboratory |
Radioimmunoassay ( Competitive - type ) |
2 |
RH01b, RH07b, RH14, RH15, CL009, CL010, CL012,
CL013, CL014a, CL015, |
Chemiluminescent Immunoassay ( Competitive - type ) |
4 |
RH01a, RH02c, RH06, RH07a, RH12, RH19, RH20,
CL005, CL006a, CL008, CL011, |
Reagent Code |
Laboratory |
|
Abbott Architect |
1 |
CL006a, CL008, RH02c, |
Beckman Coulter Access |
2 |
RH07a, RH12, RH19, |
Cisbio RIA-gnost |
3 |
CL012, CL014a, RH07b, RH14, |
Immunotech |
5 |
CL009, CL013, CL015, RH01b, |
MP |
6 |
CL010, |
Siemens ADVIA Centaur |
7 |
RH20, |
Siemens COAT-A-COUNT |
8 |
RH15, |
Siemens Immulite 2000 |
9 |
CL005, RH01a, RH06, |
Roche |
13 |
CL011, |
若有任何疑問,歡迎來電(函)聯繫或指教
財團法人預防醫學基金會
地 址:10699 台北信維郵局 624 號信箱 電 話:(02)
2703-6080
e-mail:
傳 真: (02)
2703-6070
updated
: 06 Nov, 2013